GW Pharmaceuticals plc (GWPH)
Shares of GWPH climbed $8.69 (or +8.40%) to $112.18 on Thursday’s trading session after investment analysts at Morgan Stanley initiated coverage on the company’s stock with an “Overweight” rating and a price target of $150.00.
GWPH recently reported third quarter fiscal 2015 revenues of $13.6 million
GWPHis a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas.
GWPH commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. GWPH is also advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex(R), which is in Phase 3 clinical development for the treatment of Dravet syndrome and the treatment of Lennox-Gastaut syndrome.
GWPH has a deep pipeline of additional cannabinoid product candidates which includes Sativex in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer, as well as compounds in Phase 1 and 2 clinical development for glioma, type 2 diabetes, and schizophrenia.
More about GW Pharmaceuticals plc (GWPH) atwww.gwpharm.com.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance www.finance.crwe-pr.com/disclaimer